Clinical Trial

Propofol Infusion and PONV in Cardiac Surgery

Study acronym: nausea vomitng
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 4, 2026 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this observational cohort study is to evaluate the effect of high-dose versus low-dose propofol infusion on the incidence of postoperative nausea and vomiting (PONV) in patients undergoing coronary artery bypass grafting (CABG). The study also seeks to assess the predictive performance of the Apfel and Koivuranta risk scores for PONV in the cardiac surgery population. The primary objective of this study is to determine the impact of routinely administered high-dose propofol on the incidence and severity of PONV in CABG patients. The secondary objective is to evaluate the need for antiemetic therapy during the intensive care unit stay. The investigators will compare patients receiving high-dose propofol with those receiving low-dose propofol to determine whether the antiemetic effect of propofol is dose-dependent. Participants will be asked to: Allow PONV assessments to be performed during the first 24 hours postoperatively, Provide permission for the collection of clinical data (including demographic characteristics, risk scores, opioid consumption, etc.) for research purposes.
Trial Details
NCT Number NCT07386379
Lead Sponsor Istanbul University - Cerrahpasa
Conditions Postoperative Nausea and Vomiting, Cardiovascular Surgical Procedures
Enrollment 60 participants
Start Date 2025-11-01
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-04